Novel 2-arylmethoxy-4-(2,2′-dihalogen-substituted
biphenyl-3-ylmethoxy)
benzylamine derivatives were designed, synthesized, and evaluated in vitro and in vivo against cancers as
PD-1/PD-L1 inhibitors. Through the computer-aided structural optimization
and the homogeneous time-resolved fluorescence (HTRF) assay, compound A56 was found to most strongly block the PD-1/PD-L1 interaction
with an IC50 value of 2.4 ± 0.8 nM and showed the
most potent activity. 1H NMR titration results indicated
that A56 can tightly bind to the PD-L1 protein with K
D < 1 μM. The X-ray diffraction data
for the cocrystal structure of the A56/PD-L1 complex
(3.5 Å) deciphered a novel binding mode in detail, which can
account for its most potent inhibitory activity. Cell-based assays
further demonstrated the strong ability of A56 as an
hPD-1/hPD-L1 blocker. Especially in an hPD-L1 MC38 humanized mouse
model, A56 significantly inhibited tumor growth without
obvious toxicity, with a TGI rate of 55.20% (50 mg/kg, i.g.). In conclusion, A56 is a promising clinical candidate worthy of further development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.